In solid organ transplant (SOT) the receipt of influenza vaccine in an influenza season is associated with decreased disease severity as demonstrated by the presence of pneumonia and ICU admissions. Different strategies have been assessed to optimize vaccine efficacy and immunogenicity of the influenza vaccine in the solid organ transplant recipient (SOTR). The primary objective of the study is to evaluate the immunogenicity of 2 doses of the high dose influenza vaccine utilizing neutralizing antibody assays. A control group receiving 1 HD influenza vaccine will be included.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Neutralizing antibody levels- Immunogenicity
Timeframe: Baseline
Neutralizing antibody levels- Immunogenicity
Timeframe: 4-6 weeks after dose 1
Neutralizing antibody levels- Immunogenicity
Timeframe: 3 months after 2nd dose